Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyUnique anti-PD-L1 plus chemotherapy improves OS vs. chemotherapy alone as 1st line in esophageal cancer

The phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy significantly improved OS compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form